Sanofi stock after-hours at EUR 72.81: plus 1.41 percent versus prior close
Published on 09/30/2026 at 21:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock was at EUR 72.81 after-hours at 9:15 p.m. CEST on September 30, 2026, up 1.41 percent versus the prior close at Lang & Schwarz.
Sanofi stock after the Xetra close
The prior close at Lang & Schwarz was EUR 71.80. The latest bid was EUR 72.75 and the ask was EUR 72.86. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Sanofi stock.
Planned mature-medicines partnership
In a September 14, 2026 release, Sanofi said it intends to transfer a selection of 20 mature medicines and three manufacturing sites worldwide to Cheplapharm. In return, Sanofi is to receive a 26.4 percent equity stake in Cheplapharm. The sites are in Csanyikvölgy, Hungary, Jurong, Singapore, and Ploërmel, France, with approximately 400, 100 and 65 employees, respectively.
The commercial transfer is planned to begin in the first quarter of 2027, followed by the site transfers, subject to employee consultations, regulatory approvals and customary closing conditions. Sanofi said the transaction is expected to be completed by the third quarter of 2027 and is not expected to affect its 2026 financial guidance. The medicines include Lovenox/Clexane, excluding the United States.
Earlier 2026 results
Sanofi reported in its July 30, 2026 second-quarter release that sales rose 17.8 percent at constant exchange rates and business earnings per share reached EUR 2.09. The company upgraded its 2026 guidance, expecting sales growth of around 10 percent at constant exchange rates and business EPS growth slightly faster than sales, as reported by Sanofi.
